Sunil Rajanikant Mehta
Director/Board Member at Emcure Pharmaceuticals Ltd.
Net worth: 111 $ as of 29/09/2021
Profile
Sunil Rajanikant Mehta is currently the Executive Director & Executive Director-Projects at Emcure Pharmaceuticals Ltd.
and Director at Gennova Biopharmaceuticals Ltd.
He completed his undergraduate degree from the University of Pune and his MBA from the Institute of Management, Development & Research.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
Emcure Pharmaceuticals Ltd.
Emcure Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India. 6.13% | 17/08/2021 | 11,085,012 ( 6.13% ) | 111 $ | 29/09/2021 |
Sunil Rajanikant Mehta active positions
Companies | Position | Start |
---|---|---|
Emcure Pharmaceuticals Ltd.
Emcure Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India. | Director/Board Member | 04/06/2013 |
Gennova Biopharmaceuticals Ltd.
Gennova Biopharmaceuticals Ltd. Miscellaneous Commercial ServicesCommercial Services Gennova Biopharmaceuticals Ltd. specializes in biotechnology research for biosmiliars, vaccines, and mAbs using recombinant DNA technology. The company was founded on June 19, 2001 and is headquartered in Pune, India. | Director/Board Member | 18/06/2001 |
Training of Sunil Rajanikant Mehta
University of Pune | Undergraduate Degree |
Institute of Management, Development & Research | Masters Business Admin |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Emcure Pharmaceuticals Ltd.
Emcure Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India. | Health Technology |
Gennova Biopharmaceuticals Ltd.
Gennova Biopharmaceuticals Ltd. Miscellaneous Commercial ServicesCommercial Services Gennova Biopharmaceuticals Ltd. specializes in biotechnology research for biosmiliars, vaccines, and mAbs using recombinant DNA technology. The company was founded on June 19, 2001 and is headquartered in Pune, India. | Commercial Services |
- Stock Market
- Insiders
- Sunil Rajanikant Mehta